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Objectives: To report midterm results of infrainguinal bypasses performed with a heparin-bonded expanded polytetra-
fluoroethylene (ePTFE) graft in patients presenting with critical limb ischemia.
Methods:Over a 7-year period ending in 2008, 425 patients presenting with critical limb ischemia underwent infraingui-
nal revascularization using a heparin-bonded ePTFE graft in seven Italian vascular centers. Preoperative, intraoperative,
and follow-up data were collected in a multicenter registry. Patients were predominantly male (79%) with a mean age of
73.5 years. Mean preoperative ankle brachial index (ABI) was 0.35 and 192 of the patients (45%) were diabetic.
Intervention consisted of a femoral to below-knee bypass in 324 patients (76%), whereas the remaining 101 patients had
a femoral to above-knee bypass. In patients with below-knee bypass, distal target vessels were the popliteal artery in 238
cases, the tibioperoneal trunk in 38 cases, and a tibial vessel in the remaining 48 cases (anterior tibial artery in 20 cases,
posterior tibial artery in 23 cases, and peroneal artery in 5). Follow-up consisted of clinical and duplex scanning
examinations within 3months from the intervention and yearly thereafter. Early (<30 day) results were analyzed in terms
of deaths, graft thromboses, and amputations with univariate and multivariate (stepwise logistic regression) analysis.
Follow-up results were evaluated in terms of primary and secondary graft patency, limb salvage, and survival rate with
univariate and multivariate (Cox regression) analysis.
Results: Thirteen perioperative deaths occurred (3.1%). Thirty-day primary graft patency was 92.5% and limb salvage was
95.8%. Follow-up was available in 98% of patients with a median duration of 25.5 months (SD, 17.6; range, 1-72).
Cumulative estimated 36-month primary and secondary patency, limb salvage, and survival rates were 61%, 70%, 83%,
and 83%, respectively. At univariate analysis, the factors associated with poorer limb salvage rates during follow-up were
the presence of ischemic ulcers or gangrene (log-rank, 8.4; P  .004; 95% confidence interval [CI] 1.2-3.5; odds ratio
[OR], 2.1), the presence of only one patent tibial vessel (log-rank, 41.3; P < .001; 95% CI, 3.1-10.8, OR, 5.8), redo
surgery (log-rank, 12.4; P < .001; 95% CI, 1.4-4; OR, 2.4) and the postoperative treatment with antiplatelet therapy in
comparison to oral anticoagulants (log-rank, 5.1; P  .02; 95% CI, 1.0-3.4; OR, 1.8). At multivariate analysis redo
surgery (P  .02; 95% CI, 1.1-3.1; OR, 1.8), poor runoff score (P < .001; 95% CI, 2.5-9.1; OR, 4.7) and preoperative
clinical status (P  .02; 95% CI, 1.1-3.1; OR, 1.8) were independently associated with decreased limb salvage rates.
Conclusion: The use of a heparin-bonded ePTFE graft provides good early and midterm results, with low rates of late
amputations. Primary and secondary patency made this graft an excellent alternative to autologous saphenous vein when
it is absent, unsuitable, or of poor quality. ( J Vasc Surg 2010;51:1167-77.)From the Department of Vascular Surgery, University of Florence, Florence,a
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Multiple studies and an international consensus1 have
concluded that autologous vein conduit offers better long-
term patency than prosthetic grafts in the infrainguinal
region; however, prosthetic grafts, particularly polytetra-
fluoroethylene (PTFE), provide results comparable to a
vein in the above-knee sites. In below-knee revasculariza-
tions,2,3 mid and long-term results of PTFE grafts are still
poor, with less than 50% 2-year primary patency rates.
In recent years, several modified prosthetic vascular
grafts have been developed and studied, with particular
chemical, physical, and mechanical properties aimed at
improving intrinsic thromboresistance. The use of heparin-
bonded grafts has been proposed as an alternative to auto-
logous veins to reduce both early thrombotic risk and late
myointimal hyperplasia development, due to the anti-
inflammatory properties of heparin.4
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endpoint attachment of heparin, enabling maintenance of
functional heparin bioactivity, has been developed, and its
effectiveness in terms of improvement of early graft patency
has been demonstrated in an experimental study.5 Some
clinical studies subsequently demonstrated promising re-
sults in terms of early and midterm results.6,7
The aim of this study was to evaluate early and midterm
results of above-knee and below-knee bypasses performed
with this bioactive heparin-treated expanded polytetrafluo-
roethylene (ePTFE) graft in patients with critical limb
ischemia in a multicentric retrospective registry involving
seven Italian vascular centers.
MATERIALS AND METHODS
Over a 7-year period, ending in 2008, a heparin-
bonded prosthetic graft (Propaten Gore-Tex,W.L. Gore&
Associates Inc, Flagstaff, Ariz) was implanted in 425 pa-
tients undergoing lower limb revascularization for critical
limb ischemia in seven Italian hospitals. In the same period
of time, in these seven centers, an other 155 heparin-
bonded PTFE grafts were implanted in claudicants.
Definition of critical limb ischemia was on the basis of
Trans Atlantic Inter-Societal Consensus (TASC) II recom-
mendations.1 Ultrasound scan confirmation with ankle-
brachial index (ABI) and Duplex scanner was performed in
all cases. The choice to use this graft was made on the basis
of the surgeon’s discretion and not only in the absence of a
suitable vein. Data concerning these interventions were
retrospectively collected in a multicenter registry with a
dedicateddatabase includingmainpreoperative, intraopera-
tive, and follow-up variables. Because this study is a registry
and not a randomized trial, a comparative group control
was not included. In the same period of time, 325 bypasses
with synthetic graft, 493 with autologous venous material,
and 73 composite bypasses were performed in the seven
hospitals. Formal approval for this study from the local
ethics committee was obtained.
Early (30 day) results were analyzed in terms of graft
patency, major amputation rates, andmortality. Graft patency
was defined as the possibility to maintain a functioning graft
without adjunctive interventions. Major amputation was
defined as the occurrence of amputation at above-knee
or below-knee level.
Univariate analysis for the risk of early graft thrombosis
and amputation was performed with 2 test. Multivariate
analysis (stepwise logistic regression analysis) for the same
outcomes with the inclusion of the factors resulted signifi-
cant at univariate analysis was performed. Statistical signif-
icance was defined as a P value less than .05.
Follow-up was performed within the third postopera-
tive month, at 12 months, and then yearly and consisted of
clinical examination, ABI measurements, and graft duplex
exam. Graft failure was diagnosed when ABI deterioration
was associated with Duplex scan evidence of graft throm-
bosis. Angiography and reintervention were indicated
when the recurrence of critical limb ischemia (CLI) or
acute limb ischemia occurred.Follow-up results were analyzed in terms of primary
(the possibility to maintain a functioning graft without
adjunctive interventions) and secondary (the possibility
to restore graft patency when a thrombosis occurred)
graft patency, limb salvage (the absence of amputation at
above-knee or below-knee level), and survival with uni-
variate (Kaplan-Meier curves and log-rank test) and mul-
tivariate (Cox regression) analysis. In Cox regression
analysis, the factors with statistical significance at univar-
iate analysis were included. Preoperative and postopera-
tive ABI values were compared to the t test for indepen-
dent samples. Statistical significance was defined as a
P value less than .05.
RESULTS
Demographic data. Patients were predominantly male
(338 patients, 79%), with a mean age of 73.5 years (SD 8.9).
Comorbidities and main risk factors for atherosclerosis in the
Table I. Comorbidities and common risk factors for
atherosclerosis
No. (425
patients)
Arterial hypertension 367 (86%)
History of smoking 326 (77%)
Diabetes 192 (45%)
Hyperlipemia 238 (56%
Coronary artery disease 203 (48%)
Chronic renal failure 72 (17%)
Dialysis 10 (2.5%)
SVS clinical classification
Class 4
Class 5
Class 6
230 (54%)
143 (34%)
52 (12%)
Runoff score
0-1
2-3
186 (44%)
239 (56%)
SVS, Society for Vascular Surgery.
Table II. Adjunctive procedures at proximal and distal
anastomotic sites
No. (425
patients)
Distal anastomosis site
Above-knee popliteal artery
Below-knee popliteal artery
Tibial arteries
101 (23%)
238 (56%)
86 (20%)
In-flow procedures
Ilio-femoral bypass
Iliac stenting
Femoral patching
6 (1.5%)
6 (1.5%)
18 (4%)
Out-flow procedures
Vein cuff
Patching
Tibial angioplasty
Other procedures
45 (10.5%)
23 (5%)
5 (1%)
12 (3%)whole 425 patients are summarized in Table I.
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critical limb ischemia in all patients (Rutherford class 4 in
230 patients, 54%; class 5 in 143 patients, 34%; and class 6
in the remaining 52, 12%).
Interventions were performed for occlusion of a native
vessel in 315 cases, whereas 110 patients had a reinterven-
tion for the late occlusion of a prior open or endovascular
femoropopliteal intervention.
In 186 cases (44%), one patent tibial vessel was present;
the remaining 239 patients (56%) had two or three patent
tibial vessels.
Mean preoperative ABI in the affected limb was 0.35
(SD 0.18); the value for above-knee bypasses was 0.40,
whereas the corresponding figures for below-knee and tib-
Table III. Univariate and multivariate (for significant fact
Early thromboses
Univariate a
% P
Diabetes
No diabetes
7.8%
7.2%
.8
Chronic renal failure
No chronic renal failure
5.5%
7.9%
.5
Primary intervention
Reintervention
5%
14.5%
.001
Above-knee bypass
Below-knee bypass
7%
7.7%
.8
Rest pain
Ulcers
7%
8.2%
.6
Distal procedures
No distal procedures
13%
6.1%
.03
Runoff score 0/1
Runoff score 2/3
14%
2.5%
.001
Antiplatelet
Warfarin
9%
5%
.1
CI, Confidence interval; OR, odds ratio.
Table IV. Univariate and multivariate (for significant fact
Early amputations
Univariate a
% P
Diabetes
No diabetes
4.5%
3.8%
.6
Chronic renal failure
No chronic renal failure
7%
3.5%
.2
Primary intervention
Reintervention
2.8%
8%
.01
Above-knee bypass
Below-knee bypass
0.9%
5.2%
.06
Rest pain
Ulcers
2.5%
6.5%
.07
Distal procedures
No distal procedures
7%
3.5%
.1
Runoff score 0/1
Runoff score 2/3
9%
0.5%
.001 1
Antiplatelet
Warfarin
8.5%
2.5%
.1
CI, Confidence interval; OR, odds ratio.ial interventions were 0.33 and 0.31, respectively.Surgical interventions and drug therapy. Intervention
consisted of a below-knee bypass in 324 patients (76%) and of
an above-knee revascularization in the remaining 101 pa-
tients.
Inflow vessels for bypasses were common femoral artery
in 375 cases, external iliac artery in 31 cases, and superficial
femoral artery in 19 cases.
In patients with below-knee bypass, distal target vessels
were the popliteal artery in 238 cases, the tibioperoneal
trunk in 38 cases, and a tibial vessel in the remaining 48
cases (anterior tibial artery in 20 cases, posterior tibial artery
in 23 cases, and peroneal artery in 5 cases).
Adjunctive procedures performed at proximal and dis-
tal anastomotic sites to improve run-in and runoff are
t univariate) analysis for 30-day risk of graft thrombosis
s Multivariate analysis
95% CI 95% CI OR P
0.5-2.2 —
0.2-2.0 —
1.6-6.6 1.2-5.4 2.5 .01
0.3-2.1 —
0.6-2.4 —
1.0-4.8 0.6-3.1 1.4 .4
2.5-15.6 2.1-13.5 5.3 .001
0.2-1.1 —
t univariate) for 30-day risk of limb loss
s Multivariate analysis
95% CI 95% CI OR P
0.4-3.1 —
0.2-1.2 —
1.1-7.8 0.16-1.12 0.43 .09
0.02-1.3 —
0.8-3.1 —
0.3-1.1
1.5-70.8 2.8-16.4 5.2 .003
0.1-1.4 —ors a
nalysi
OR
1.02
0.68
3.12
0.89
1.19
2.25
6.3
0.52ors a
nalysi
OR
1.20
0.67
3.03
0.18
1.6
0.58
0.5
0.45reported in Table II. Most distal adjunctive procedures
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whereas patients with above-knee bypasses had a distal
adjunctive procedure in only 14 cases (13%).
All the patients had intraoperative administration of 30
to 70 IU/Kg of intravenous heparin at arterial clamping,
on the basis of the surgeon’s preferences and habits.
Postoperative and long-term medical treatment con-
sisted of single antiplatelet therapy in 221 cases, double
antiplatelet therapy in 43 cases, and oral anticoagulants in
161 patients, the regimen for anticoagulation or antiplate-
lets being determined just on the basis of the surgeon’s
preference.
Platelet count was routinely monitored in the preoper-
ative period and in the immediate postoperative period, but
not during follow-up.
Early results. There were 13 perioperative deaths,
3024181260
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24,000 
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Fig 1. Kaplan-Meyer curve for estimatwith a mortality rate of 3% (confidence interval [CI], 1.7-5.5); the cause of death was cardiac in 10 patients, whereas
the remaining 3 patients suffered from a fatal pulmonary
embolism, an ischemic stroke, and sepsis, respectively. One
perioperative severe bleeding (requiring surgical revision at
the distal anastomosis) occurred. No case of postoperative
heparin-induced thrombocytopenia (HITT) was recorded.
Early graft thrombosis occurred in 32 patients (7.5%;
CI, 5.5-11.7), with a cumulative 30-day graft patency
rate of 92.5%. There were 18 early major amputations,
with a 30-day major amputation rate of 4.2% (CI, 2.6-
7.1).
Univariate analysis demonstrated that patients with
redo surgery, a poor runoff score, and the need for
adjunctive distal procedures were more likely to have
early graft thrombosis, whereas only redo surgery and
poor runoff score were associated with higher perioper-
Events 
Cumulative 
primary 
patency at 
each interval  SE 
45 .89 .02 
16 .85 .02 
16 .80 .02 
6 .78 .02 
14 .75 .02 
9 .71 .02 
5 .69 .02 
2 .68 .03 
5 .66 .03 
1 .66 .03 
6 .63 .03 
2 .61 .03 
-month primary patency with life table.36
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8ative amputation rates (Tables III and IV). At multivar-
d 36-
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independently associated with a higher risk of graft failure
(P .01; 95% CI, 1.21-5.4; odds ratio [OR], 2.5; P .001;
95% CI, 2.1-13.5; OR, 5.3), whereas only poor runoff score
was found to independently affect perioperative limb loss (P
.003; 95% CI, 2.8-16.4; OR, 5.2).
Follow-up results. Median duration of follow-up was
25.5months (range, 1-72months); 420 patients (98%) had
at least one postoperative clinical and ultrasonographic
examination, and 312 patients (73%) reached at least a
1-year follow-up.
Mean ABI value during follow-up was 0.76 (compared
to 0.35 preoperatively; P  .001). The value for above-
knee bypasses was 0.80, whereas the corresponding figures
for below-knee and tibial interventions were 0.76 and 0.61,
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Fig 2. Kaplan-Meyer curve for estimaterespectively.During follow-up, 50 deaths, 108 new graft thrombo-
ses, and 35 major amputations occurred.
In 11 of 108 cases of late thrombosis, intermittent
claudication was present and no further surgical procedure
was attempted. In the remaining cases, acute or critical
ischemia was present and a new open or endovascular
(thrombolysis with or without percutaneous transluminal
angioplasty) procedure was performed, leading to a sec-
ondary patency in 33 cases. In 13 cases a new bypass was
successfully placed. In 33 cases of graft thrombosis ampu-
tation was necessary.
The cumulative rate of amputations (both periopera-
tive and during follow-up) was significantly higher in Soci-
ety for Vascular Surgery (SVS) class 6 patients (14 ampu-
tations out of 52 patients; 27%) than in class 4 and 5 (10%
Events 
Cumulative 
secondary 
patency at 
each interval SE 
30 .93 .01 
14 .89 .02 
8 .87 .02 
4 .85 .02 
16 .82 .02 
7 .78 .02 
4 .77 .02 
1 .76 .02 
4 .75 .02 
2 .74 .02 
5 .71 .03 
1 .70 .03 
month secondary patency with life table.36
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12and 16.5%, respectively; P .007). In 39 of 52 SVS class 6
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ankle amputation, and in the remaining cases with limited
toe amputations.
There were 4 graft infections, and in 3 of these patients
major amputation was required (in 2 cases with patent
graft). No cases of late HITT were reported.
Cumulative survival rate at 36months was 83%. Cumu-
lative estimated 12, 24, and 36-month primary patency
rates were 75%, 66%, and 61%, respectively (Fig 1). The
corresponding 12, 24, and 36-month data for secondary
patency were 82%, 75%, 70%, respectively (Fig 2), and for
limb salvage 88.%, 85%, and 83%, respectively (Fig 3).
No significant difference in terms of late outcomes was
found when analyzing the results of each single clinical
center.
Univariate analysis for factors affecting primary pa-
tency and limb salvage during follow-up are shown in
3024181260
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Time (months) Number at risk Censored
,000 420 
3,000 365 
6,000 340 
9,000 306 
12,000 295 
15,000 257 
18,000 241 
21,000 209 
24,000 198 
27,000 170 
30,000 158 
33,000 137 
Fig 3. Kaplan-Meyer curve for estimTables V and VI.We did not find any difference between above-knee,
below-knee, and tibial revascularizations in terms of both
primary patency (log-rank 4.7; P  .09) and limb salvage
(log-rank 2.7; P  .2) at univariate analysis (Figs 4 and 5).
At Cox regression analysis, both redo surgery (P .01;
95% CI, 1.1-2.2; OR, 1.6) and poor runoff score (P 
.001; 95% CI, 1.2-2.4; OR, 1.7) were associated with
long-term poorer primary patency rates. Redo surgery (P
.01; 95% CI, 1.1-3.1; OR, 1.8), poor runoff score (P 
.001; 95% CI, 2.5-9.1; OR, 4.7), and preoperative clinical
status (P  .02; 95% CI, 1.1-3.1; OR, 1.8) were also
independently associated with lower-limb salvage rates.
There was a trend toward poorer 36-month primary
patency rates when a distal adjunctive procedure was per-
formed in below-knee popliteal bypasses (41%, and 64%
when distal procedures were not required; log-rank, 3; P
.08), but not in tibial bypasses (38% and 50%, respectively;
Events 
Cumulative 
limb salvage at 
each interval SE 
23 .94 .01 
12 .91 .01 
3 .90 .01 
1 .90 .02 
8 .88 .02 
2 .87 .02 
1 .86 .02 
0 .86 .02 
2 .85 .02 
1 .85 .02 
3 .83 .02 
1 .83 .02 
6-month limb salvage with life table.36
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13log-rank, 0.9; P  .3).
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Surgical revascularization with femoropopliteal bypass
is a safe and effective method of treatment in patients with
critical limb ischemia, providing good early and long-term
patency and limb salvage rates.1,8 In this era of increased
utilization of endovascular procedures, the TASC II con-
sensus still recommends surgical bypass in complex and
extensive femoropopliteal arterial disease. The only ran-
domized trial comparing surgical and endovascular treat-
ments failed to demonstrate the superiority of one method
over the other.9 The primary problem in lower-limb revas-
cularization continues to be the significant rate of early and
late graft failure, ranging from 25% to 35% at 2 years.10 The
risk of graft thrombosis is greater in the early postoperative
period but remains substantial even after the first postop-
erative year.11
The ideal material for below-knee revascularizations is
autologous saphenous vein, which has been demonstrated
to provide significantly better results than prosthetic
grafts.12 When autologous veins are not suitable, the most
commonly used synthetic material is ePTFE, which has
provided results similar to those achieved with autologous
vein in above-knee revascularizations in the first 24 postop-
erative months,11 but poorer results in below-knee inter-
ventions.2
For these reasons, attempts have been made to de-
velop prosthetic materials with intrinsic thrombosis re-
Table V. Univariate and multivariate (for significant facto
Univariate an
Log-rank P
Diabetes 0.7 .4
Chronic renal failure 0.6 .4
Reintervention 12.1 .001
Tibial anastomosis 4.7 .09
Rutherford’s class 5-6 2.8 .09
Distal procedures 2.2 .1
Runoff score 0-1 15.3 .001
Antiplatelet treatment 0.2 .7
CI, Confidence interval; OR, odds ratio.
Table VI. Univariate and multivariate (for significant fact
Univariate an
Log-rank P
Diabetes 2.9 .08
Chronic renal failure 1.9 .1
Reintervention 12.4 .001
Tibial anastomosis 2.7 .7
Rutherford’s class 5-6 8.4 .004
Distal procedures 2.8 .09
Runoff score 0-1 41.3 .001
Antiplatelet treatment 5.1 .02
CI, Confidence interval; OR, odds ratio.sistance due to modifications of chemical and physicalgraft properties. Particularly, the use of heparin bonded
to biomaterial surfaces13 has been proposed both to
reduce graft thrombogenicity, due to its interaction with
the thrombin-antithrombin system, and to inhibit the
formation of myointimal hyperplasia at anastomotic
sites.14
With the indexed ePTFE graft, heparin does not simply
cover the graft surface but is immobilized on the graft,
producing a surface microstructure having stable, covalently
bound heparin. The covalent endpoint linkagesmaintain their
bioactivity on the antithrombin sites of the bound heparin up
to 12 weeks postimplantation, offering a uniform surface
heparinization, sustained in vivo heparin bioactivity, and
increased antithrombotic and anti-inflammatory proper-
ties, as demonstrated by experimental studies.5
Results from our multicenter registry confirmed earlier
results in terms of excellent safety, with a negligible rate of
perioperative bleeding requiring surgical revision, graft pa-
tency, and amputation rates.6,7,15-17 We did not find any
differences in terms of early graft failure between above-
knee and below-knee revascularizations, although there
was a trend toward better perioperative limb salvage rates in
above-knee interventions. As described previously,18 we
noticed a significantly higher percentage of early graft
thromboses and amputations in patients undergoing redo
procedures and in patients with preoperative poor runoff
status. Moreover, the need for adjunctive procedures at
univariate) analysis for primary patency during follow-up
Multivariate analysis
% CI OR 95% CI OR P
6-1.2 0.9
5-1.3 0.8
2-2.5 1.8 1.1-2.2 1.6 .01
0-1.7 1.3
9-1.8 1.3
9-1.9 1.3
3-2.6 1.9 1.2-2.4 1.75 .001
6-1.3 0.9
t univariate) analysis for limb salvage during follow-up
Multivariate analysis
% CI OR 95% CI OR P
-1.1 0.6
-1.2 0.6
-4 2.4 1.1-3.1 1.8 .01
-2 1.3
-3.5 2.1 1.1-3.1 1.8 .02
-2.8 1.6
-10.8 5.8 2.5-9.1 4.7 .001
-3.4 1.8 0.5-1.7 0.9 .9rs at
alysis
95
0.
0.
1.
1.
0.
0.
1.
0.ors a
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95
0.3
0.3
1.4
0.9
1.2
0.9
3.1
1.0distal anastomotic sites was associated with poorer periop-
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Site of distal 
anastomosis Time (months) 
Number at 
risk Censored Events 
Cumulative 
primary patency at 
each interval SE 
AK ,000 100 11 10 .89 .03
3,000 79 3 5 .84 .04
6,000 71 7 1 .82 .04
9,000 63 3 1 .81 .04
12,000 59 3 1 .80 .04
15,000 55 2 2 .77 .05
18,000 51 4 2 .74 .05
21,000 45 1 1 .72 .05
24,000 43 4 0 .72 .05
27,000 39 4 0 .72 .05
30,000 35 10 0 .72 .05
33,000 25 1 0 .72 .05
BK ,000 236 18 21 .91 .02
3,000 197 7 9 .87 .02
6,000 181 12 9 .82 .03
9,000 160 4 4 .80 .03
12,000 152 12 10 .75 .03
15,000 130 4 4 .72 .03
18,000 122 20 3 .70 .03
21,000 99 4 1 .70 .03
24,000 94 17 3 .67 .03
27,000 74 6 0 .67 .03
30,000 68 5 4 .63 .04
33,000 59 5 2 .61 .04
Tibial ,000 82 3 14 .83 .04
3,000 65 3 2 .80 .04
6,000 60 2 6 .72 .05
9,000 52 3 1 .70 .05
12,000 48 3 3 .66 .05
15,000 42 2 3 .61 .06
18,000 37 2 0 .61 .06
21,000 35 2 0 .61 .06
24,000 33 1 2 .57 .06
27,000 30 0 1 .55 .06
30,000 29 1 2 .52 .06
33,000 26 2 0 .52 .06
Fig 4. Kaplan-Meyer curve for estimated 36-month primary patency on the basis of the level of distal anastomosis
(AK: above-knee, BK: below-knee) with life table.
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AK ,000 100 13 2 .98 .01
3,000 85 4 2 .96 .02
6,000 79 10 0 .96 .02
9,000 69 4 0 .96 .02
12,000 65 4 2 .92 .03
15,000 59 3 1 .91 .03
18,000 55 5 1 .89 .04
21,000 49 3 0 .89 .04
24,000 46 4 0 .89 .04
27,000 42 3 1 .87 .04
30,000 38 10 0 .87 .04
33,000 28 2 0 .87 .04
BK ,000 236 16 12 .95 .01
3,000 208 6 9 .91 .02
6,000 193 15 2 .90 .02
9,000 176 3 0 .90 .02
12,000 173 19 4 .87 .02
15,000 150 9 1 .87 .02
18,000 140 24 0 .87 .02
21,000 116 5 0 .87 .02
24,000 111 19 1 .86 .02
27,000 91 6 0 .86 .02
30,000 85 7 2 .84 .03
33,000 76 9 1 .83 .03
Tibial ,000 84 3 9 .89 .03
3,000 72 3 1 .88 .04
6,000 68 6 1 .86 .04
9,000 61 3 1 .85 .04
12,000 57 7 2 .82 .04
15,000 48 2 0 .82 .04
18,000 46 2 0 .82 .04
21,000 44 3 0 .82 .04
24,000 41 3 1 .80 .05
27,000 37 2 0 .80 .05
30,000 35 1 1 .77 .05
33,000 33 2 0 .77 .05
Fig 5. Kaplan-Meyer curve for estimated 36-month limb salvage on the basis of the level of distal anastomosis (AK:
above-knee, BK: below-knee) with life table.
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cedures were used more frequently in patients with poor
runoff status, with severe clinical conditions (grade 5 and 6
of Rutherford’s classification), and in reinterventions.
Median duration of follow-up in our registry was 25.5
months, which is similar to the recent study from Daenens
et al.20 Our estimated 36-months survival rate (83%) might
seem high, considering the poor clinical condition of our
patients. However, we have to underline that more than
50% of our patients had rest pain, a condition probably with
a better prognosis than the presence of ulcers or gangrene.
Our estimated 36-month curves demonstrated a cumula-
tive limb salvage rate higher than 80% with a primary
patency rate of about 60%; even in the absence of a control
group of patients undergoing unmodified ePTFE bypass in
this study, these results compare well to recently reported
36-month 40.8% primary patency in a meta-analysis of
infrapopliteal ePTFE grafts.2
Even if the number of above-knee revascularizations in
our series was low, thus limiting the statistical power of our
findings in this subgroup of patients, our results in this
subgroup of patients were satisfactory, with primary pa-
tency and limb salvage rates at 3 years approaching 70% and
90%, respectively.
Results in below-knee revascularizations were satisfac-
tory too, with 61% primary patency and 83% limb salvage
rates at 3 years, which are comparable to results obtained
with Propaten graft in other series.20,21 Also, in femo-
rotibial bypasses, results were encouraging without statisti-
cal differences with below-knee revascularizations. It could
be suggested that prolonged heparin bioactivity on the
graft surface does influence the formation of anastomotic
myointimal hyperplasia, improving long-term patency
rates.4 It could also be suggested that sustained heparin
activity may reduce thrombus accumulation, thereby de-
creasing the scaffold available for both mid graft and anas-
tomotic remodeling events.
Univariate analysis demonstrated that redo surgery and
a poor runoff status were associated with poorer primary
patency during follow-up, and this was also in Cox’s regres-
sion analysis.
Patients undergoing reintervention with ulcers and
poor runoff status and postoperatively treated with anti-
platelet therapy were more likely to have amputation dur-
ing follow-up at univariate and, with the exception of drug
treatment, at multivariate analysis. These findings support
the need for continuing to use autologous materials in
these subgroups of patients.
On the contrary, the good results at 3 years in primary
interventions in patients with more than one patent distal
vessel and with rest pain could suggest a significant role of
this heparin-bonded graft in these subgroups of patients.
Also, Daenens et al20 recently reported in a retrospec-
tive nonrandomized study of similar rates of graft patency
and limb salvage at 2 years between heparin-bonded
ePTFE and autologous saphenous vein, and suggested the
routine use of this graft when there is any doubt regarding
the quality of autologous veins.The present study has several limits, primarily its retro-
spective nature, the varied criteria for patient selection, the
variable medical therapy between the different centers, and
the absence of a control group with patients treated with
unmodified ePTFE grafts. Moreover, estimates of graft
patency and amputation rates could be biased by the com-
peting risk of death for these other two outcomes, poten-
tially reducing the strength of our results.
To overcome these limits, a prospective multicenter
registry has been designed including the same seven Italian
centers, has already received the approval from the different
local ethical committees, and is ready to begin enrollment
this year.
CONCLUSIONS
Data from this large, retrospective registry confirmed
that the indexed heparin-bonded ePTFE graft provides
satisfactory early and midterm results in patients undergo-
ing surgical treatment of critical limb ischemia. Primary and
secondary patency rates make this graft an excellent alter-
native to autologous saphenous vein when it is absent,
unsuitable, or of poor quality.
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